|Bid||50.90 x 1800|
|Ask||51.05 x 2900|
|Day's range||50.28 - 51.15|
|52-week range||41.45 - 61.71|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||9.79|
|Earnings date||06 Feb 2023 - 10 Feb 2023|
|Forward dividend & yield||1.60 (3.23%)|
|Ex-dividend date||03 Nov 2022|
|1y target est||54.78|
Pfizer Inc is investing more than $2.5 billion at its drug making plants in Belgium and Ireland, gearing up to launch new products it hopes can replace lost revenue as patents expire and COVID-19 vaccine sales decline. The drugmaker said on Friday it plans to spend more than 1.2 billion euros ($1.26 billion) to expand its Puurs, Belgium manufacturing site, matching the investment at its Dublin, Ireland plant announced on Thursday. The Puurs site has played a key role in the production of COVID-19 vaccine shots Pfizer developed with its German partner BioNTech using the messenger RNA (mRNA) technology.
The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis.
Beijing will be unable to control the spread of Covid-19 unless it imports foreign-made vaccines that are more effective than Chinese-made jabs, Joe Biden’s coronavirus tsar has warned. Ashish Jha, who runs the US coronavirus response, said in an interview at a conference organised by the FT and the Commonwealth Fund that all the empirical evidence suggests Chinese-made Covid vaccines are “not as good” as mRNA shots made by Moderna, BioNTech and Pfizer. Other Covid vaccines based on different technologies developed in the UK and elsewhere, such as the University of Oxford-AstraZeneca jab, are also superior to vaccines made in China, he added.